Quick facts
| Members of the class | semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide |
|---|---|
| Brand names in the class | OzempicWegovyRybelsusMounjaroZepboundVictozaSaxendaTrulicityByettaBydureon BCise |
| Drug class | GLP-1 receptor agonists (and the dual GIP/GLP-1 receptor agonist tirzepatide) |
| Generally used for | A class of injectable and oral medicines used to lower blood sugar in type 2 diabetes and, for several of them, to treat obesity and overweight with weight-related conditions. |
Health Captain explains what a medicine is generally used for, how its class works, and what to discuss with your care team. We never publish dosing, and this page cannot account for your medical history, kidney or liver function, pregnancy, or the other medicines you take. This is education, not prescribing advice — follow the instructions on your label and ask your prescriber or pharmacist.
What is GLP-1 Receptor Agonists?
GLP-1 receptor agonists copy a gut hormone released after eating. They prompt insulin release when glucose is high, damp down glucagon, slow how fast the stomach empties, and reduce appetite signaling in the brain. Some are approved for type 2 diabetes, some for weight management, and some for both. Tirzepatide acts on the GIP receptor as well as GLP-1.
Key takeaways
- These medicines work with the body’s own post-meal hormone signaling rather than forcing insulin release regardless of glucose.
- Nausea and other digestive effects are the most common side effects and are the usual reason a prescriber adjusts the plan.
- Not every product in this class is approved for both diabetes and weight management — the approved use differs by brand.
- The class carries an FDA boxed warning based on thyroid C-cell tumors in rodents; it is not prescribed for people with a personal or family history of medullary thyroid carcinoma or MEN 2.
- This page is general education, not prescribing advice — whether this medicine is right for you, and how it is dosed, is individualized and decided by you and your prescriber.
How it generally works
After a meal your gut releases a hormone called GLP-1. It tells the pancreas to release insulin when blood sugar is climbing, tells it to hold back glucagon (the hormone that raises blood sugar), and slows how quickly the stomach empties so glucose arrives in the bloodstream more gradually. Your own GLP-1 breaks down within minutes; these medicines are engineered to last far longer, so the same signals stay switched on.
The same receptors sit in appetite-regulating parts of the brain, which is why people commonly describe feeling full sooner and thinking about food less. Tirzepatide adds a second target, the GIP receptor, and is described as a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist. Because insulin release is glucose-dependent, these medicines used alone rarely push blood sugar too low.
Common side effects
Most people tolerate GLP-1 Receptor Agonists well, and many effects settle as the body adjusts. Tell your prescriber or pharmacist about anything that persists or bothers you.
- Nausea, particularly early on and after larger or richer meals
- Vomiting or retching
- Diarrhea or, just as often, constipation
- Burping, reflux, and a feeling of fullness that lasts unusually long
- Reduced appetite and early satiety
- Fatigue or headache
- Injection-site redness or itching with the injectable forms
Serious side effects
These are uncommon, but they are the ones to act on rather than wait out. Contact a clinician promptly if you notice any of them. If you believe you are experiencing a medical emergency, call emergency services immediately (911 in the United States).
- Severe, persistent upper abdominal pain, often boring through to the back, with vomiting — the pattern associated with pancreatitis
- A neck lump, hoarseness that does not resolve, trouble swallowing, or shortness of breath — symptoms the labeling asks patients to report because of the thyroid C-cell tumor signal
- Right upper abdominal pain, fever, or yellowing of the skin or eyes — may reflect gallbladder disease, which occurs more often with rapid weight loss
- Vomiting that prevents keeping fluids down, or a rapidly worsening ability to eat — reports of gastroparesis (delayed stomach emptying) have led to labeling changes
- New or worsening vision changes in people with diabetic retinopathy — rapid improvement in glucose can transiently worsen retinopathy
Important warnings
FDA boxed warning
A boxed warning is the strongest warning the US Food and Drug Administration applies to a medicine. It does not mean nobody should take it — it means the risk below is serious enough that it must be weighed deliberately with your prescriber.
- Thyroid C-cell tumors — the class carries an FDA boxed warning. Rodents given these medicines developed thyroid C-cell tumors; whether this happens in humans is not established. They are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Other warnings and precautions
- Pancreatitis — cases have been reported. These medicines are generally stopped if pancreatitis is suspected and not restarted if it is confirmed.
- Delayed gastric emptying — labeling has been updated to reflect reports of gastroparesis and of retained stomach contents. Tell any anaesthetist or proceduralist that you take a GLP-1 medicine before sedation or surgery.
- Hypoglycemia in combination — used with insulin or a sulfonylurea, the risk of low blood sugar rises and the prescriber may change those medicines.
- Pregnancy — these medicines are generally stopped before a planned pregnancy; the labeling advises discontinuing them when pregnancy is recognized. Weight-management products in particular are not for use in pregnancy.
- Gallbladder disease and kidney injury — gallstones and cholecystitis are reported, and dehydration from vomiting or diarrhea has been linked to acute kidney injury.
Drug interactions
Interactions are one of the most common avoidable medication problems. Keep one list of everything you take — including supplements and over-the-counter products — with the Medication List Builder, and read our guide to drug interactions.
- Insulin and sulfonylureas — combining these raises hypoglycemia risk; prescribers often adjust the other medicine.
- Oral medicines with a narrow margin between effective and toxic — slowed stomach emptying can change how quickly some oral drugs are absorbed.
- Oral semaglutide specifically — absorption is highly sensitive to food and other oral medicines taken at the same time, so timing instructions come from the pharmacist.
- Alcohol — can worsen nausea and, with insulin or sulfonylureas in the mix, contribute to low blood sugar.
- Sedation and general anaesthesia — professional societies have issued guidance about food in the stomach; this is a safety interaction with procedures rather than with another drug.
Monitoring
What a care team typically keeps an eye on while someone is taking GLP-1 Receptor Agonists. The exact schedule is individual.
- A1C every three to six months when used for diabetes
- Weight and waist measurements when used for weight management
- Kidney function, particularly after any episode of prolonged vomiting or diarrhea
- Retinal examination as scheduled for people with diabetic retinopathy
- Symptom review for abdominal pain, persistent vomiting, or neck lumps at each visit
Storage
- Unopened injectable pens are refrigerated; do not freeze them, and do not use a pen that has been frozen.
- In-use pens have their own storage rules that differ by product — the carton and the patient instructions state the room-temperature limit for that specific pen.
- Keep pens capped, protected from light, and away from the freezer compartment and the refrigerator door if the label says so.
- Dispose of needles and pens in an FDA-cleared sharps container, not in household rubbish.
Questions for your doctor or pharmacist
Pharmacists are the most under-used resource in medicine, and the conversation is usually free. Build an agenda with Appointment Prep.
- Can we go through my full medication list together — prescriptions, over-the-counter products, vitamins, herbal products, and supplements — to check for interactions, duplicates, and anything I no longer need?
- Is this product approved for the reason I am taking it — blood sugar, weight, cardiovascular risk reduction, or a combination?
- Do I have any personal or family history of medullary thyroid cancer or MEN 2 that would rule this out?
- What should I do if nausea or vomiting stops me eating and drinking normally?
- Do any of my other diabetes medicines need to change when I start this?
- What is the plan if I stop — what typically happens to weight and blood sugar afterwards?
- If I have a procedure with sedation coming up, what do I need to tell the team?
Frequently asked questions
Is tirzepatide a GLP-1 medicine?
Partly. Tirzepatide activates the GLP-1 receptor and also the GIP receptor, so it is properly described as a dual GIP/GLP-1 receptor agonist. It is usually discussed alongside the GLP-1 class because the practical experience — appetite reduction, digestive side effects, similar warnings — overlaps closely, but it is a distinct molecule with its own labeling.
What happens if I stop taking a GLP-1 medicine?
The hormonal signal stops with the drug. In trials of weight-management products, most participants regained a substantial share of the weight they had lost after discontinuation, and blood sugar tends to drift back up in people treated for diabetes. This is why these are generally framed as long-term treatments rather than short courses. Discuss any stop with your prescriber.
Do these medicines cause thyroid cancer?
That is not established in people. The boxed warning comes from rodent studies in which these medicines caused thyroid C-cell tumors. Human relevance is unknown, and the labeling responds by ruling out use in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and by asking patients to report neck lumps or persistent hoarseness.
Are compounded versions the same thing?
No. Compounded semaglutide or tirzepatide products are not FDA-approved, are not reviewed for safety, effectiveness, or quality, and FDA has warned about dosing errors and about products containing salt forms that were never studied. If cost is the barrier, ask your prescriber about approved alternatives and patient assistance rather than sourcing a compounded version.
Sources
- MedlinePlus — Drugs, Herbs and Supplements — Plain-language drug information from the US National Library of Medicine; search for semaglutide, tirzepatide, liraglutide, or dulaglutide.
- DailyMed — GLP-1 receptor agonist labeling — The current FDA-approved prescribing information submitted by manufacturers.
- FDA — Drug Safety and Availability — Safety communications, label changes, recalls, and shortage notices.
- American Diabetes Association — Specialty society guidance on glucose-lowering and weight-management therapy.
- NIDDK — Diabetes — US National Institutes of Health patient information on diabetes treatment.
Health Captain links to primary public-health and clinical sources so you can read the original material yourself. See our sources policy.